Increased activity of Pgp multidrug transporter in patients with Helicobacter pylori infection

Table 2 Role of pretherapeutic determination of Pgp activity.

Variables	Therapy cycle			B/A and controls
	H pylori positive		H pylorinegative
	1 = A (n = 20)	2 or more = B (n = 33)	NO (n = 12)	Pa	Beta Pb
Age (yr)	47.5±8.8	47.3±13.7	48.3±16.5	0.973	0.152
Sex (M/ F)	9/11	15/18	5/7	0.975	0.153
DHP	2.75±0.91	2.90±0.97	1.0±0.0	0.00001	0.00065
DIEn	2.65±0.81	3.06±0.86	1.0±0.0	0.00001	0.45
RMF (mean±SD)	0.889±0.28	1.647±0.65	0.787±0.29	0.00001	0.000005

H pylori positive patients: A = one therapy cycle, B = two or more therapy cycles; NO = no therapy, M = male; F = female; DHP = H pylori density; DIEn = density of intraepithelial neutrophil infiltration; RMF = ratio of mean fluorescences, Pa for analysis of variance, Pb for multiple regression analysis.